Complement Split Product C3d As an Indicator of Disease Activity in Systemic Lupus Erythematosus

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 1993 Mar 1

PMID 8467609

Citations 11

Authors

E Rother

B Lang

R Coldewey

K Hartung

H H Peter

Affiliations

Soon will be listed here.

Abstract

In order to investigate, if complement levels can be used as an indicator of clinical activity in systemic lupus erythematosus (SLE), levels of C3, C4, CH50, and C3d were measured in 79 patients, 41 with inactive, 31 with moderately active and 7 with severely active disease. Our study shows that C3d, and particularly the C3d/C3 ratio, provide sensitive markers for disease activity in SLE. Since C3d is a direct measurement of complement turnover, it reflects complement activation better than C3, C4 and CH50.

Citing Articles

Detection and functional resolution of soluble immune complexes by an FcγR reporter cell panel.

Chen H, Maul-Pavicic A, Holzer M, Huber M, Salzer U, Chevalier N EMBO Mol Med. 2021; 14(1):e14182.

PMID: 34842342 PMC: 8749491. DOI: 10.15252/emmm.202114182.

Systemic complement activation levels in Stargardt disease.

Dhooge P, Runhart E, Li C, de Kat Angelino C, Hoyng C, van der Molen R PLoS One. 2021; 16(6):e0253716.

PMID: 34170959 PMC: 8232401. DOI: 10.1371/journal.pone.0253716.

Complement Activation Levels Are Related to Disease Stage in AMD.

Heesterbeek T, Lechanteur Y, Lores-Motta L, Schick T, Daha M, Altay L Invest Ophthalmol Vis Sci. 2020; 61(3):18.

PMID: 32176267 PMC: 7401663. DOI: 10.1167/iovs.61.3.18.

The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus.

Troldborg A, Jensen L, Deleuran B, Stengaard-Pedersen K, Thiel S, Jensenius J Front Immunol. 2018; 9:581.

PMID: 29632534 PMC: 5879092. DOI: 10.3389/fimmu.2018.00581.

Systemic complement activation in central serous chorioretinopathy.

van Dijk E, Tsonaka R, Klar-Mohamad N, Wouters D, de Vries A, de Jong E PLoS One. 2017; 12(7):e0180312.

PMID: 28671968 PMC: 5495432. DOI: 10.1371/journal.pone.0180312.

References

Brandslund I, Siersted H, Svehag S, Teisner B . Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma. J Immunol Methods. 1981; 44(1):63-71. DOI: 10.1016/0022-1759(81)90107-1. View

Inman R, Fong J, Pussell B, Ryan P, Hughes G . The C1q binding assay in systemic lupus erythematosus: discordance with disease activity. Arthritis Rheum. 1980; 23(11):1282-6. DOI: 10.1002/art.1780231109. View

Isenberg D, Shoenfeld Y, Schwartz R . Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. Arthritis Rheum. 1984; 27(2):132-8. DOI: 10.1002/art.1780270203. View

Perrin L, Lambert P, MIESCHER P . Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J Clin Invest. 1975; 56(1):165-76. PMC: 436567. DOI: 10.1172/JCI108065. View

Clough J, Chang R . Effectiveness of testing for anti-DNA and the complement components iC3b, Bb, and C4 in the assessment of activity of systemic lupus erythematosus. J Clin Lab Anal. 1990; 4(4):268-73. DOI: 10.1002/jcla.1860040407. View

Stannat S, Bahlmann J, Kiessling D, Koch K, Deicher H, Peter H . Complement activation during hemodialysis. Comparison of polysulfone and cuprophan membranes. Contrib Nephrol. 1985; 46:102-8. View

Sekita K, Doi T, Muso E, Yoshida H, Kanatsu K, Hamashima Y . Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus. Clin Exp Immunol. 1984; 55(3):487-94. PMC: 1535930. View

Hartung K, Fontana A, Klar M, Krippner H, Jorgens K, Lang B . Association of class I, II, and III MHC gene products with systemic lupus erythematosus. Results of a Central European multicenter study. Rheumatol Int. 1989; 9(1):13-8. DOI: 10.1007/BF00270284. View

Negoro N, Okamura M, Takeda T, Koda S, Amatsu K, Inoue T . The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus. Arthritis Rheum. 1989; 32(10):1233-42. DOI: 10.1002/anr.1780321008. View

10.

Bourke B, Moss I, Maini R . Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis. J Immunol Methods. 1982; 48(1):97-108. DOI: 10.1016/0022-1759(82)90214-9. View

11.

Kerr L, Adelsberg B, SCHULMAN P, Spiera H . Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity. Arthritis Rheum. 1989; 32(11):1406-13. DOI: 10.1002/anr.1780321109. View

12.

Kingsmore S, Thompson J, Crockard A, Todd D, McKirgan J, Patterson C . Measurement of circulating immune complexes containing IgG, IgM, IgA and IgE by flow cytometry: correlation with disease activity in patients with systemic lupus erythematosus. J Clin Lab Immunol. 1989; 30(1):45-52. View

13.

Isenberg D, Colaco C, Dudeney C, Todd-Pokropek A, Snaith M . The relationship of anti-DNA antibody idiotypes and anti-cardiolipin antibodies to disease activity in systemic lupus erythematosus. Medicine (Baltimore). 1986; 65(1):46-55. DOI: 10.1097/00005792-198601000-00003. View

14.

ter Borg E, Horst G, Hummel E, Limburg P, Kallenberg C . Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 1990; 33(5):634-43. DOI: 10.1002/art.1780330505. View

15.

Swaak A, Aarden L, Statius van Eps L, FELTKAMP T . Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum. 1979; 22(3):226-35. DOI: 10.1002/art.1780220304. View

16.

Tan E, Cohen A, Fries J, MASI A, McShane D, Rothfield N . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11):1271-7. DOI: 10.1002/art.1780251101. View

17.

Hopkins P, Belmont H, Buyon J, Philips M, Weissmann G, Abramson S . Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum. 1988; 31(5):632-41. DOI: 10.1002/art.1780310508. View

18.

Morrow W, Isenberg D, Todd-Pokropek A, Parry H, Snaith M . Useful laboratory measurements in the management of systemic lupus erythematosus. Q J Med. 1982; 51(202):125-38. View

19.

Morrow W, Williams D, Ferec C, Casburn-Budd R, Isenberg D, Paice E . The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 1983; 42(6):668-71. PMC: 1001326. DOI: 10.1136/ard.42.6.668. View

20.

Swaak A, Groenwold J, Aarden L, Statius van Eps L, Feltkamp E . Prognostic value of anti-dsDNA in SLE. Ann Rheum Dis. 1982; 41(4):388-95. PMC: 1000956. DOI: 10.1136/ard.41.4.388. View